Publicaciones en las que colabora con Marisol Aymerich Soler (15)

2021

  1. Expression of endothelial nox5 alters the integrity of the blood-brain barrier and causes loss of memory in aging mice

    Antioxidants, Vol. 10, Núm. 8

  2. Understanding the potential role of sirtuin 2 on aging: Consequences of sirt2.3 overexpression in senescence

    International Journal of Molecular Sciences, Vol. 22, Núm. 6, pp. 1-23

2017

  1. GPR55: A therapeutic target for Parkinson's disease?

    Neuropharmacology, Vol. 125, pp. 319-332

2016

  1. Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease

    Brain, Behavior, and Immunity, Vol. 57, pp. 94-105

2014

  1. The monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model

    Neurobiology of Aging, Vol. 35, Núm. 11, pp. 2603-2616

2013

  1. A simple and efficient method for the production of human glycosylated glial cell line-derived neurotrophic factor using a Semliki Forest virus expression system

    International Journal of Pharmaceutics, Vol. 440, Núm. 1, pp. 19-26

2011

  1. Long-term neuroprotection and neurorestoration by glial cell-derived neurotrophic factor microspheres for the treatment of Parkinson's disease

    Movement Disorders, Vol. 26, Núm. 10, pp. 1943-1947

2010

  1. Production of highly pure human glycosylated GDNF in a mammalian cell line

    International Journal of Pharmaceutics, Vol. 385, Núm. 1-2, pp. 6-11

2009

  1. Effective GDNF brain delivery using microspheres-A promising strategy for Parkinson's disease

    Journal of Controlled Release, Vol. 135, Núm. 2, pp. 119-126

2008

  1. Controlled drug delivery to the brain: an overview

    Handbook of particulate drug delivery (American Scientific Publishers), pp. 121 - 142

  2. Sustained release of bioactive glycosylated glial cell-line derived neurotrophic factor from biodegradable polymeric microspheres

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 69, Núm. 3, pp. 844-851

2007

  1. Microencapsulación de factores neurotróficos: Aplicación al tratamiento de la enfermedad de Parkinson

    Mapfre Medicina, Vol. 18, Núm. 4, pp. 240-248

  2. Purification of bioactive glycosylated recombinant glial cell line-derived neurotrophic factor

    International Journal of Pharmaceutics, Vol. 344, Núm. 1-2, pp. 9-15

2006

  1. Expresión y purificación de GDNF para su microencapsulación y aplicación en la enfermedad de Parkinson

    Mapfre Medicina, Vol. 17, Núm. 3, pp. 166-171

  2. Terapias neuroprotectoras y neurorestauradoras en el tratamiento de la enfermedad de Parkinson

    Anales del sistema sanitario de Navarra, Vol. 29, Núm. 3, pp. 325-335